CE Holdings Q3 FY2025 slides: Healthcare solutions drive record revenue growth

CE Holdings (TSE:4320) reported record-high Q3 FY2025 sales of 12,320 million yen (+12.8% YoY) and operating profit of 1,195 million yen (+68.9% YoY), primarily driven by strong performance in its electronic medical record (EMR) systems business. The company significantly revised its FY2025 profit attributable to owners forecast upwards to 1,550 million yen, largely due to a special income from the partial transfer of its Micron subsidiary shares to Tigermed Japan, transitioning Micron to an equity-method affiliate. With a strong market position in Japanese hospitals under 300 beds and a substantial untapped market where nearly half of these facilities lack EMR systems, CE Holdings is well-positioned for continued growth despite the operational impact of the Micron transaction.

Analysis

CE Holdings (TSE:4320) demonstrated significant operational strength in its Q3 FY2025 results, posting record-high sales and profits. Revenue grew 12.8% year-over-year to 12,320 million yen, while operating profit surged an impressive 68.9% to 1,195 million yen, driven primarily by the high-margin Healthcare Solutions Business. This core segment, focused on electronic medical record (EMR) systems, saw its own profit increase 53.7%. Forward-looking indicators support a positive outlook, with record order intake rising 13.7% and the order backlog growing 7.3%, providing strong revenue visibility. The company's strategic positioning within its target market of Japanese hospitals with fewer than 300 beds remains a key asset, as nearly half of this segment (approximately 3,300 hospitals) has yet to adopt EMR systems, representing a substantial runway for growth.

The revised full-year guidance requires nuanced interpretation due to the strategic partial sale of its Micron subsidiary. While the deconsolidation of Micron led to a downward revision of the operating profit forecast to 1,400 million yen, this figure still represents a robust 21.9% year-over-year increase, confirming the underlying health of the remaining core operations. Conversely, the forecast for profit attributable to owners was substantially increased to 1,550 million yen, a figure inflated by the one-time special income from the share transfer. This M&A activity, while creating a significant non-recurring gain, transitions Micron to an equity-method affiliate, which could provide long-term benefits through its new partnership with Tigermed Japan.

Key Decisions for Investors

• Investors should recognize the strong underlying fundamentals evident in the 68.9% YoY surge in Q3 operating profit and record order intake, which signal continued momentum in the core EMR business.
• It is crucial to analyze the revised FY2025 guidance by separating the one-time net profit gain from the Micron share sale from the core operational outlook; the revised operating profit, despite a downward revision due to deconsolidation, still projects a robust 21.9% year-over-year increase.
• Long-term value will be driven by the company's ability to capture share within the significantly underpenetrated market of smaller Japanese hospitals, making market penetration progress a key metric to monitor.